Related Experiment Video

Updated: Mar 9, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells

Mahamat Babagana1, Sydney Johnson1, Hannah Slabodkin1

  • 1Department of Cell Stress Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York.

Molecular Carcinogenesis
|January 5, 2017
PubMed

Insights

Targeting p21-activated kinases (PAKs) can enhance BRAF-inhibitor (BRAFi) therapy effectiveness. Inhibiting PAK1 overcomes BRAFi resistance in cancer cells, suggesting a new strategy to improve anti-cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • BRAF mutations drive many cancers, making BRAF-inhibitors (BRAFi) a key therapeutic target.
  • Intrinsic resistance and acquired drug resistance limit the clinical efficacy of BRAFi.
  • Developing strategies to enhance BRAFi efficacy and overcome resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of p21-activated kinases (PAKs), specifically PAK1, in mediating response to BRAF-inhibitors (BRAFi).
  • To determine if modulating PAK1 activity can overcome BRAFi resistance in cancer cells.
  • To explore the potential of combining PAK and BRAF inhibitors for cancer therapy.

Main Methods:

  • Assessed the effect of BRAFi on active PAK1 levels in cancer cells.
  • Utilized genetic and pharmacologic methods to manipulate PAK1 activity.
  • Investigated the impact of PAK1 modulation on BRAFi sensitivity and resistance.
  • Examined the combined effects of PAK and BRAF inhibitors on resistant cancer cells.

Main Results:

  • BRAFi treatment reduced active PAK1 levels.
  • Activated PAK1 conferred BRAFi resistance, while PAK1 inhibition sensitized cells to BRAFi.
  • PAK inhibition negated the BRAFi-tolerance conferred by AKT1 and RAC1 activation.
  • Combined PAK and BRAF inhibition showed synergistic effects on intrinsically BRAFi-resistant cells.

Conclusions:

  • PAK1 plays a significant role in BRAFi response and resistance.
  • Inhibition of PAK1 can sensitize cancer cells to BRAFi and overcome resistance mechanisms.
  • Combining PAK inhibitors with BRAFi represents a promising strategy to augment anti-cancer therapy, particularly for BRAFi-resistant tumors.
Keywords:
AZD6244MAP Kinase CascadePF3758309melanomavemurafenib

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K